Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Addex Therapeutics Ltd., a foreign private issuer based in Geneva, Switzerland, for the month of July 2022. The filing, dated July 22, 2022, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release rather than a financial statement containing quantitative data.
Material Changes
No material financial changes versus prior periods are detailed in the text of this filing. The primary content is the notification of the press release dated July 22, 2022.
Guidance, Outlook, and Risks
The filing does not contain management commentary, guidance, outlook, or specific risk factors within its body text. These details are contained within the attached press release (Exhibit 99.1), which is incorporated by reference into the company's registration statements on Form F-3 and Form S-8.
Key Facts for Investor Verification
- Review the full text of the press release dated July 22, 2022 (Exhibit 99.1) for the specific corporate announcement.
- Verify the incorporation of this press release into the active registration statements (Form F-3 No. 333-255089 and Form S-8 No. 333-255124).
- Note that this filing contains no standalone financial data; all quantitative metrics must be sourced from the referenced exhibit or other periodic reports.